FDA issues draft guidances on compounding

FDA's Center for Drug Evaluation and Research (CDER) released four draft guidances addressing the agency's regulation of drug compounding.

The Avastin bevacizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY), a humanized mAb against VEGF that is frequently used off-label in place of Lucentis ranibizumab from Genentech and Novartis AG (NYSE:NVS; SIX:NOVN). ...